Capstone Investment Advisors
VTGN icon

Capstone Investment Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Capstone Investment Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,172
Closed -$267K – 1884
2021
Q1 		$267K Buy
4,172
+1,786
+75% +$119K ﹤0.01% 1375
2020
Q4 		$139K Buy
+2,386
New +$60.9K ﹤0.01% 1510

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capstone Investment Advisors's VTGN Position: Q2 2021 in Review

Capstone Investment Advisors sold out of VistaGen Therapeutics (VTGN) in Q2 2021, closing a stake of 4,172 shares — an estimated $267K sold.

Capstone Investment Advisors first reported a position in VTGN in Q4 2020 and held it in 2 quarters. The position peaked at $267K in Q1 2021. 101 funds tracked by Wall St. Rank hold VTGN as of Q2 2021.

  • Capstone Investment Advisors reported no remaining VistaGen Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 4,172 VistaGen Therapeutics shares in Q2 2021, an estimated $267K.
  • Capstone Investment Advisors first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 2 quarters.
  • Capstone Investment Advisors's VistaGen Therapeutics position peaked at $267K in Q1 2021.
  • 101 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2021.

Based on Capstone Investment Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.